{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:05:23Z","timestamp":1790366723252,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1097\/spc.0b013e328133f2ad","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T11:47:44Z","timestamp":1209901664000},"page":"35-39","source":"Crossref","is-referenced-by-count":12,"title":["Irinotecan toxicity"],"prefix":"10.1097","volume":"1","author":[{"given":"Lowell","family":"Anthony","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210126","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","article-title":"Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer","volume":"21","author":"Fuchs","year":"2003","journal-title":"J Clin Oncol"},{"key":"R2-9-20210126","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/dji242","article-title":"Cetuximab therapy and symptomatic hypomagnesemia","volume":"97","author":"Schrag","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R3-9-20210126","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res"},{"key":"R4-9-20210126","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/01.cad.0000167902.53039.5a","article-title":"Liposomal encapsulated anticancer drugs","volume":"16","author":"Hofheinz","year":"2005","journal-title":"Anti-Cancer Drugs"},{"key":"R5-9-20210126","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1200\/JCO.2005.01.008","article-title":"Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors","volume":"23","author":"Soepenberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"R6-9-20210126","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/jnci\/87.24.1876","article-title":"Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum","volume":"87","author":"Ikuno","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"R7-9-20210126","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","article-title":"Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients","volume":"13","author":"Abigerges","year":"1995","journal-title":"J Clin Oncol"},{"key":"R8-9-20210126","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tips.2006.06.007","article-title":"TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?","volume":"27","author":"Maitland","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"R9-9-20210126","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/1078-0432.CCR-03-0548","article-title":"Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients","volume":"10","author":"Rouits","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R10-9-20210126","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1998.16.8.2745","article-title":"Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment","volume":"16","author":"Saliba","year":"1998","journal-title":"J Clin Oncol"},{"key":"R11-9-20210126","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1158\/1078-0432.CCR-05-2152","article-title":"Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction","volume":"12","author":"Schaaf","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R12-9-20210126","first-page":"4187","article-title":"Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11","volume":"51","author":"Kawato","year":"1991","journal-title":"Cancer Res"},{"key":"R13-9-20210126","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s002800050595","article-title":"Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital","volume":"39","author":"Gupta","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"R14-9-20210126","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1023\/A:1008261821434","article-title":"Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports","volume":"8","author":"Wasserman","year":"1997","journal-title":"Ann Oncol"},{"key":"R15-9-20210126","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JCO.2005.03.2847","article-title":"Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors","volume":"24","author":"Furman","year":"2006","journal-title":"J Clin Oncol"},{"key":"R16-9-20210126","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2004.11.125","article-title":"Phase II study of activated charcoal to prevent irinotecan-induced diarrhea","volume":"22","author":"Michael","year":"2004","journal-title":"J Clin Oncol"},{"key":"R17-9-20210126","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2005.03.0239","article-title":"Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with nonsmall-cell lung cancer treated with irinotecan and cisplatin","volume":"24","author":"Han","year":"2006","journal-title":"J Clin Oncol"},{"key":"R18-9-20210126","first-page":"843","article-title":"UGT1A1 genotyping in patients undergoing treatment with irinotecan","volume":"3","author":"Innocenti","year":"2005","journal-title":"Clin Adv Hematol Oncol"},{"key":"R19-9-20210126","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01213011-200505000-00004","article-title":"Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes","volume":"15","author":"Innocenti","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R20-9-20210126","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2005.05.2464","article-title":"Irinogenetics: what is the right star?","volume":"24","author":"Innocenti","year":"2006","journal-title":"J Clin Oncol"},{"key":"R21-9-20210126","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2004.01.950","article-title":"Irinotecan pharmacogenetics: is it time to intervene?","volume":"22","author":"McLeod","year":"2004","journal-title":"J Clin Oncol"},{"key":"R22-9-20210126","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/1078-0432.1226.11.3","article-title":"UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine\/irinotecan","volume":"11","author":"Carlini","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R23-9-20210126","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan","volume":"22","author":"Innocenti","year":"2004","journal-title":"J Clin Oncol"},{"key":"R25-9-20210126","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2005.05.5400","article-title":"The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer","volume":"24","author":"Toffoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"R26-9-20210126","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/jcp.2004.022319","article-title":"5-Fluorouracil\/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case","volume":"58","author":"Steiner","year":"2005","journal-title":"J Clin Pathol"},{"key":"R27-9-20210126","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200111013451818","article-title":"Toxicity of irinotecan in patients with colorectal cancer","volume":"345","author":"Van Cutsem","year":"2001","journal-title":"N Engl J Med"},{"key":"R28-9-20210126","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.2001.19.15.3456","article-title":"Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients","volume":"19","author":"Falcone","year":"2001","journal-title":"J Clin Oncol"},{"key":"R29-9-20210126","first-page":"289","article-title":"Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): results from the Eastern Cooperative Oncology Group (ECOG) Study E2200","volume":"23","author":"Giantonio","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R30-9-20210126","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R31-9-20210126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1634\/theoncologist.6-1-81","article-title":"Irinotecan plus fluorouracil\/leucovorin for metastatic colorectal cancer: a new survival standard","volume":"6","author":"Saltz","year":"2001","journal-title":"Oncologist"},{"key":"R32-9-20210126","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"R33-9-20210126","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ctrv.2005.12.011","article-title":"Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties","volume":"32","author":"Biasco","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"R34-9-20210126","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"key":"R35-9-20210126","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jamcollsurg.2005.01.024","article-title":"Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases","volume":"200","author":"Fernandez","year":"2005","journal-title":"J Am Coll Surg"},{"key":"R36-9-20210126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin in Liver Dis"},{"key":"R37-9-20210126","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","article-title":"Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases","volume":"24","author":"Vauthey","year":"2006","journal-title":"J Clin Oncol"},{"key":"R38-9-20210126","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"R39-9-20210126","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/jco.2006.24.18_suppl.8506","article-title":"Phase III double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea during pelvic radiation therapy: results of North Central Cancer Treatment Group protocol N00CA","volume":"18S","author":"Martenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"R40-9-20210126","first-page":"289","article-title":"A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial","volume":"4","author":"Rosenoff","year":"2006","journal-title":"J Support Oncol"}],"container-title":["Current Opinion in Supportive & Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0b013e328133f2ad","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T03:26:36Z","timestamp":1684380396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-200704000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e328133f2ad","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}